|
 |
ForticalThis page contains recent news articles, when available, and an overview of Fortical but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Fortical ® , Unigene’s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Business Wire (press release), Do You Know How to Spray? How to Use Fortical Nasal Spray - Jul 29, 2008 A question from a reader: Dr. Mike, I've read the directions for using Fortical used as a nose spray, but I’m not sure I’m using it right. About.com - Drugs, Unigene CEO Discusses Value of Peptides and Company's Technologies ... - Jul 10, 2008 Fortical(R), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. FOXBusiness Understanding Risk Factors, Screening, and Treatment of ... - Jul 22, 2008 Salmon calcitonin (Miacalcin; Novartis, East Hanover, New Jersey; Fortical; Upsher Smith Pharmaceuticals, Maple Grove, Minnesota) is a peptide sequence that Ortho SuperSite, QualityStocks.net News – Unigene Laboratories Inc. (UGNE.OB) - Jul 11, 2008 Fortical ® , Unigene’s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. TransWorldNews (press release), Unigene CEO Discusses Value of Peptides and Company's Technologies ... - Jul 10, 2008 Fortical(R), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. PR-Inside.com (Pressemitteilung), Unigene Announces Financial Results For First Quarter 2008 - May 12, 2008 Revenue for both periods primarily consisted of Fortical sales and royalties, which were $3791000 for the three months ended March 31, 2008, and $4461000 Business Wire (press release), Unigene to Release First Quarter 2008 Results and Host Conference Call - May 8, 2008 Fortical ® , Unigene’s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Business Wire (press release), Osteoporosis: An Equal Opportunity Illness - May 9, 2008 It is available today in a prescription drug called Fortical from Upsher-Smith Laboratories. Unigene is also developing an oral version of the product. Newswise (press release) Seniors II 2008 Feature Releases - May 19, 2008 He has worked to create a nasal calcitonin treatment for osteoporosis sufferers called Fortical. Calcitonin, a naturally-occurring hormone that helps the Centre Daily Times, Unigene Joint Venture Breaks Ground for Global Biotechnology Park ... - 23 Apr 2008 Fortical ® , Unigene’s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Business Wire (press release), Unigene to Present at the 20th Annual Roth Capital Partners Growth ... - Feb 13, 2008 Fortical(R), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. FOXBusiness Boning up on New Osteoporosis Risk Guidelines - Mar 10, 2008 Calcitonin is the active ingredient in Fortical, a nasal treatment developed by Unigene and marketed by Upsher-Smith Laboratories. Business Wire (press release), Osteoporosis is traditionally thought of as a women's disease ... - Feb 18, 2008 It is available today in a prescription drug called Fortical from Upsher-Smith Laboratories. Unigene is also developing an oral version of the product. PR-Inside.com (Pressemitteilung), UGNE: FDA Approves Modification for Key Enzyme in Fortical(R) - Jan 17, 2008 ...patented manufacturing process for calcitonin, the active ingredient in Fortical(R), Unigene's nasal spray product for the treatment of osteoporosis. Trading Markets (press release), Unigene and Shijiazhuang Pharmaceutical Group to Expand Chinese ... - Jan 8, 2008 Fortical(R), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. FOX News Does Early Bone Loss Mean You Need Drugs? - Jan 30, 2008 Drug options include bisphosphonates such as Fosamax, Boniva, and Actonel; calcitonins such as Fortical and Miacalcin; estrogen and hormone therapy; U.S. News & World Report, No Bones about It - Jan 17, 2008 Calcitonin is the active ingredient in Fortical, a nasal calcitonin treatment developed by Unigene and marketed by Upsher-Smith Laboratories. Business Wire (press release), Real Progress Underway in China Biotech - Jan 13, 2008 The new company will produce Unigene’s osteoporosis drug, the nasal spray Fortical, using a new biologic process to produce the drug. Seeking Alpha, Unigene Expanding in China - Jan 8, 2008 The United States’ rights to Fortical, Unigene’s nasal spray for the treatment of osteoporosis in post-menopausal women, are licensed to Upsher-Smith NJBIZ, Unigene Announces Financial Results for the Third Quarter of 2007 - Nov 12, 2007 Revenue from Fortical sales and royalties was $5771000 and $13607000, respectively, for the three months and nine months ended September 30, 2007. Business Wire (press release), Unigene to Release Third Quarter Results and Host Conference Call ... - Nov 7, 2007 Fortical ® , Unigene’s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Business Wire (press release), Metastatic Carcinoma of the Long Bones - Nov 13, 2007 Treatment with calcitonin (Fortical) is not supported by evidence. A Cochrane review based on limited studies found that calcitonin does not significantly AAFP News Now Unigene and Yale Present Longer-Term Animal Data for Novel Site ... - Sep 20, 2007 Fortical ® , Unigene’s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Business Wire (press release), Will Follow-On Biologics Bill Become Law? - Sep 17, 2007 However, the agency has approved some follow-on biologics under the FD&C Act, such as GlucaGen, Hydase, Fortical and Omnitrope. The Senate Health, Education Patent Baristas, Unigene to Present at the ROTH 2007 New York Conference - Aug 29, 2007 Fortical(R), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Genetic Engineering News (press release), Unigene Announces Financial Results for the Second Quarter of 2007 - Aug 10, 2007 Revenue from Fortical sales and royalties was $3374000 and $7836000, respectively, for the three months and six months ended June 30, 2007. Business Wire (press release), Unigene initiated with "market perform" - Aug 8, 2007 ...company has achieved significant success commercially with Fortical, its lead product for osteoporosis, which commands 46% market share domestically. newratings.com Biotech Faces 'Perfect Storm' As Lawmakers Return to the Fray - Aug 31, 2007 However, the agency has approved some follow-on biologics under the FD&C Act, such as GlucaGen, Hydase, Fortical and Omnitrope, Janet Woodcock, FDA's deputy BioWorld Online, ROTH 2007 New York Conference Presenter Profiles - Sep 4, 2007 Fortical(R), our nasal spray formulation of calcitonin for the treatment of osteoporosis, received FDA approval and was launched in August 2005. TMC Net, Unigene Initiates Oral Calcitonin Clinical Study in Humans - Aug 2, 2007 Genetic Engineering News (press release),Fortical(R), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene and Yale Present Novel Site-Directed Bone Growth ... - Jun 27, 2007 Genetic Engineering News (press release),Fortical(R), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene Announces Strong Increase in Revenue and Improved ... - May 11, 2007 Genetic Engineering News (press release),Fortical royalties for the three months ended March 31, 2007 increased to $1845000 from $198000 for the three months ended March 31, 2006. FDA to Biotech Investors: Relax, You Have Years Before Competition ... - Mar 27, 2007 Patent Baristas,Hydase (hyaluronidase), Fortical (calcitonin salmon recombinant) Nasal Spray, Amphadase (hyaluronidase), GlucaGen (glucagon recombinant for injection), Unigene Engages University Clinicians to Advise on Bone Growth Program - Nov 30, 2006 dBusinessNews New York (press release),Fortical®, Unigene’s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |